Comparison of Intranasal Ciclesonide, Oral Levocetirizine, and Combination Treatment for Allergic Rhinitis

Title
Comparison of Intranasal Ciclesonide, Oral Levocetirizine, and Combination Treatment for Allergic Rhinitis
Author(s)
김창훈[김창훈]김진국[김진국]김현준[김현준]조진희[조진희]김정수[김정수]김용대이흥만[이흥만]김성완[김성완]조규섭[조규섭]이상학[이상학]이재서[이재서]동헌종[동헌종]나기상[나기상]윤주헌[윤주헌]
Keywords
PERSISTENT ASTHMA; NASAL AEROSOL; EFFICACY; CLASSIFICATION; GUIDELINE; DIAGNOSIS; ADULTS
Issue Date
201503
Publisher
KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY
Citation
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, v.7, no.2, pp.158 - 166
Abstract
Purpose: To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Methods: Subjects exhibiting moderate to severe allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 mu g ciclesonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by reflective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ). Results: Significant improvements in rT.NSS, PANS, and RQLQ in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were well tolerated alone and in combination. Conclusions: Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not give further clinical benefit over monotherapy.
URI
http://hdl.handle.net/YU.REPOSITORY/33233http://dx.doi.org/10.4168/aair.2015.7.2.158
ISSN
2092-7355
Appears in Collections:
의과대학 > 이비인후과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE